次世代組織バイオマーカーの世界市場：市場規模・シェア・動向分析 (製品種類別・技術別・用途別・最終用途別・地域別)、セグメント別予測 (2025年～2030年)

次世代組織バイオマーカー市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の次世代組織バイオマーカーの市場規模は2030年までに59億8,000万米ドルに達すると予測され、予測期間中に12.74％のCAGRで成長すると予測されています。

慢性疾患の有病率の増加、バイオマーカー検出技術の技術的進歩、個別化医薬品に対する需要の高まりなどの主な促進要因が市場成長の要因となっています。糖尿病、がん、その他の自己免疫疾患などの慢性疾患の発生率は世界的に増加しています。

次世代の組織バイオマーカーを検出するための技術進歩の増加が市場の成長を後押ししています。次世代シーケンシング（NGS）などのハイスループットスクリーニング技術の開発により、がん組織の遺伝子変異や遺伝子発現プロファイルを解析する能力が大幅に向上しています。さらに、リキッドバイオプシー、ハイスループットスクリーニング技術、エピジェネティックプロファイリング、マイクロRNAベースのバイオセンサーは、次世代組織バイオマーカー検出のために実用化されています。これらの技術的進歩を総称すると、組織バイオマーカー探索の状況は一変し、より正確な診断、個別化された治療戦略、患者転帰の改善につながります。AIと機械学習アルゴリズムはデジタル病理学に組み込まれ、組織画像の解析を自動化しています。個別化医薬品に対する需要の高まりも、市場成長の主要因です。こうした個別化医療では、次世代組織バイオマーカーを活用し、個々の患者に合わせた治療を行うケースが増えています。

バイオマーカーの検出に関しては、エピゲノム研究ツールのアリダ・バイオサイエンシズ（AlidaBio）が2025年2月、EpiPlexプラットフォームの本格的な商業化を正式に発表しました。この画期的なプラットフォームは、ショートリードシーケンスにより複数のRNA修飾を同時に検出・定量し、同時に遺伝子発現データも提供する初めてのものです。

2025年2月、ゲノムソリューションを提供するバイオフィデリティ社は、幅広い応用が期待できる革新的なターゲット濃縮技術であるEnspyreの発売に関する詳細を発表しました。バックグラウンドDNAを選択的に除去することで、次世代シーケンシング（NGS）の効率を大幅に向上させる画期的なターゲット濃縮技術。

2024年9月、RNAバイオマーカー企業であるGenialis社は、異なる組織型や変異型にわたってKRAS阻害剤（KRASi）に対する患者の反応性と臨床的有用性を予測できる初のバイオマーカーアルゴリズムであるGenialis krasIDの発売を発表しました。Genialis krasIDは、化合物／MOAの分化や選択といった前臨床の初期段階から臨床試験まで、薬剤開発の指針を支援することができます。

2024年10月、もう一つの新規老化細胞標的分子が開発されました。DNAシーケンシングとアレイベース技術の企業であるイルミナ社は、本日、ラボにおける次世代シーケンシング（NGS）を強化するため、比類のないベンチトップスピードと使いやすさを提供するシーケンシングシステムMiSeq i100シリーズを発表しました。

2021年9月、ロシュはAVENIO Tumor Tissue CGP Kitの発売を発表しました。この新しいキットは、RocheとFoundation Medicineの既存のCGPポートフォリオを強化するもので、研究室が社内でより広範な腫瘍学研究を実施できるようになります。このキットの導入により、集中的な検査室を通じて当社の検査にアクセスすることができない検査室に対して、社内のソリューションを提供することで、ゲノム・プロファイリングへの世界のアクセスが大幅に増加することになる、と同社は述べています。

次世代組織バイオマーカー市場：分析概要

• 製品別では、試薬・アッセイが2024年に55.97%の最大売上シェアを占めました。この分野は、バイオ医薬品研究への幅広い適用性から、急速な拡大が見込まれています。主な促進要因は、疾病の早期発見と診断に対するニーズの高まりであり、その結果、正確で信頼性の高い迅速な診断に対する需要が高まり、市場成長に寄与しています。
• 種類別では、ゲノムバイオマーカーのセグメントが2024年の市場を独占しました。これは、革新的な治療法に対する需要の高まり、疾病の早期発見をめぐる競合の激化、多額の研究開発投資によるものです。メタボロームバイオマーカーは予測期間中に最も急成長が見込まれます。メタボロームバイオマーカーとは、体内の特定の代謝変化や物質を測定し、疾患状態の特定、疾患リスクの予測、治療に対する反応のモニタリングに利用できるものを指します。
• 技術別では、次世代シーケンシングのセグメントが2024年に最大の収益シェアで市場を独占しました。次世代シーケンシング（NGS）とは、ゲノム探索を支援する巨大なDNAシーケンシング法を指します。空間ゲノミクス生物学セグメントは、2024年から2030年にかけて最も速いCAGRで成長すると予測されています。CRISPR/Cas9システムなどのゲノム編集ツールの進歩が空間ゲノミクス生物学の採用を促進し、市場成長を牽引しています。
• 用途別では、腫瘍分野が2024年に最大の収益シェアで市場を独占しました。精密医療に対する需要の高まりが、同分野の成長と標的がん治療を牽引しています。コンパニオン診断薬は予測期間中に最も急成長が見込まれます。コンパニオン診断薬市場は製品拡大が著しく、さまざまながんタイプ、自己免疫疾患、神経疾患向けに新しいアッセイが開発されています。
• 最終用途別では、病院・参照検査室部門が2024年に最大の収益シェアを獲得し、市場を独占しました。病院や参照検査室は、効率性、正確性、アクセス性を高めるために次世代組織バイオマーカーを急速に採用しています。CROは、予測期間中に大きく成長すると予測されています。

目次

第1章 分析方法・範囲

第2章 エグゼクティブサマリー

第3章 次世代組織バイオマーカー市場：変動要因・傾向・範囲

• 市場連関の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場促進要因の分析
  • 市場抑制要因の分析
• 次世代組織バイオマーカー市場：分析ツール
  • 業界分析：ポーターのファイブフォース分析
  • PESTEL分析

第4章 次世代組織バイオマーカー市場：製品別の推定・動向分析

• セグメントダッシュボード
• 次世代組織バイオマーカー市場：製品別の変動分析
• 次世代組織バイオマーカーの市場規模と動向分析：製品別（2018～2030年）
• 試薬・アッセイ
• 装置・プラットフォーム
• ソフトウェア・AI

第5章 次世代組織バイオマーカー市場：種類別の推定・動向分析

• 市場シェア：種類別（2024年・2030年）
• セグメントダッシュボード
• 次世代組織バイオマーカー市場：種類別の展望
• 市場規模の予測と動向分析：種類別（2018～2030年）
• ゲノムバイオマーカー
• プロテオームバイオマーカー
• プロテオームバイオマーカー
• エピジェネティックバイオマーカー
• トランスクリプトミクスバイオマーカー
• メタボロミクスバイオマーカー

第6章 次世代組織バイオマーカー市場：技術別の推定・動向分析

• 市場シェア：技術別（2024年・2030年）
• セグメントダッシュボード
• 次世代組織バイオマーカー市場：製品別の変動分析
• 次世代組織バイオマーカーの市場規模と動向分析：製品別（2018～2030年）
• 免疫組織化学
• 次世代シーケンシング（NGS）
• 質量分析（MS）に基づくプロテオミクス
• 空間生物学プラットフォーム
• デジタル病理学とAI分析
• その他

第7章 次世代組織バイオマーカー市場：用途別の推定・動向分析

• 市場シェア：用途別（2024年・2030年）
• セグメントダッシュボード
• 次世代組織バイオマーカー市場：用途別の変動分析
• 次世代組織バイオマーカーの市場規模と動向分析：用途別（2018～2030年）
• 腫瘍
• コンパニオン診断
• 創薬・医薬品開発
• 神経学
• その他

第8章 次世代組織バイオマーカー市場：最終用途の推定・動向分析

• 市場シェア：最終用途別（2024年・2030年）
• セグメントダッシュボード
• 次世代組織バイオマーカー市場：最終用途別の変動分析
• 次世代組織バイオマーカーの市場規模と動向分析：最終用途別（2018～2030年）
• 病院・参照検査室
• 製薬・バイオテクノロジー企業
• 学術研究機関
• CRO（医薬品開発業務受託機械）

第9章 次世代組織バイオマーカー市場：地域別の推定・動向分析

• 市場シェア分析：地域別（2024年・2030年）
• 市場ダッシュボード：地域別
• 世界市場のスナップショット：地域別
• 市場規模の予測と動向分析（2018～2030年）
• 北米
  • 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • ノルウェー
  • スウェーデン
  • デンマーク
• アジア太平洋
  • アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第10章 競合情勢

• 最近の動向と影響分析：主要市場参入企業別
• 企業/競合の分類
• ベンダー情勢
  • 主要な流通業者・チャネルパートナーの一覧
  • 主要顧客
  • 主要企業の市場シェア分析 (2024年)
  • Roche Diagnostics/Ventana Medical Systems
  • Agilent Technologies/Dako
  • Thermo Fisher Scientific
  • Leica Biosystems（Danaher Corporation）
  • Illumina
  • Qiagen
  • NeoGenomics
  • NanoString Technologies
  • Akoya Biosciences
  • Bio-Techne/ACD
  • Guardant Health

List of Tables

• Table 1 List of abbreviations
• Table 2 North America Next Generation Tissue Biomarkers market, by region, 2018 - 2030 (USD Million)
• Table 3 North America Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 4 North America Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
• Table 5 North America Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 6 North America Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 7 North America Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)
• Table 8 U.S Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 9 U.S Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
• Table 10 U.S Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 11 U.S Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 12 U.S Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)
• Table 13 Canada Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 14 Canada Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
• Table 15 Canada Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 16 Canada Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 17 Canada Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)
• Table 18 Mexico Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 19 Mexico Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
• Table 20 Mexico Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 21 Mexico Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 22 Mexico Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)
• Table 23 Europe Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 24 Europe Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
• Table 25 Europe Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 26 Europe Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 27 Europe Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)
• Table 28 UK Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 29 UK Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
• Table 30 UK Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 31 UK Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 32 UK Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)
• Table 33 Germany Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 34 Germany Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
• Table 35 Germany Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 36 Germany Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 37 Germany Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)
• Table 38 France Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 39 France Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
• Table 40 France Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 41 France Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 42 France Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)
• Table 43 Italy Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 44 Italy Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
• Table 45 Italy Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 46 Italy Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 47 Italy Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)
• Table 48 Spain Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 49 Spain Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
• Table 50 Spain Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 51 Spain Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 52 Spain Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)
• Table 53 Denmark Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 54 Denmark Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
• Table 55 Denmark Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 56 Denmark Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 57 Denmark Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)
• Table 58 Sweden Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 59 Sweden Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
• Table 60 Sweden Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 61 Sweden Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 62 Sweden Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)
• Table 63 Norway Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 64 Norway Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
• Table 65 Norway Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 66 Norway Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 67 Norway Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)
• Table 68 Asia Pacific Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 69 Asia Pacific Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
• Table 70 Asia Pacific Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 71 Asia Pacific Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 72 Asia Pacific Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)
• Table 73 Japan Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 74 Japan Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
• Table 75 Japan Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 76 Japan Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 77 Japan Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)
• Table 78 China Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 79 China Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
• Table 80 China Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 81 China Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 82 China Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)
• Table 83 India Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 84 India Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
• Table 85 India Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 86 India Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 87 India Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)
• Table 88 Australia Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 89 Australia Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
• Table 90 Australia Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 91 Australia Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 92 Australia Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)
• Table 93 South Korea Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 94 South Korea Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
• Table 95 South Korea Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 96 South Korea Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 97 South Korea Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)
• Table 98 Thailand Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 99 Thailand Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
• Table 100 Thailand Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 101 Thailand Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 102 Thailand Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)
• Table 103 Latin America Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 104 Latin America Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
• Table 105 Latin America Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 106 Latin America Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 107 Latin America Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)
• Table 108 Brazil Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 109 Brazil Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
• Table 110 Brazil Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 111 Brazil Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 112 Brazil Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)
• Table 113 Argentina Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 114 Argentina Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
• Table 115 Argentina Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 116 Argentina Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 117 Argentina Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)
• Table 118 MEA Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 119 MEA Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
• Table 120 MEA Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 121 MEA Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 122 MEA Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)
• Table 123 South Africa Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 124 South Africa Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
• Table 125 South Africa Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 126 South Africa Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 127 South Africa Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)
• Table 128 Saudi Arabia Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 129 Saudi Arabia Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
• Table 130 Saudi Arabia Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 131 Saudi Arabia Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 132 Saudi Arabia Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)
• Table 133 UAE Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 134 UAE Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
• Table 135 UAE Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 136 UAE Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 137 UAE Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)
• Table 138 Kuwait Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 139 Kuwait Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
• Table 140 Kuwait Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 141 Kuwait Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 142 Kuwait Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Primary interviews in North America
• Fig. 5 Primary interviews in Europe
• Fig. 6 Primary interviews in APAC
• Fig. 7 Primary interviews in Latin America
• Fig. 8 Primary interviews in MEA
• Fig. 9 Market research approaches
• Fig. 10 Value-chain-based sizing & forecasting
• Fig. 11 QFD modeling for market share assessment
• Fig. 12 Market formulation & validation
• Fig. 13 Next Generation Tissue Biomarkers market: market outlook
• Fig. 14 Next Generation Tissue Biomarker competitive insights
• Fig. 15 Parent market outlook
• Fig. 16 Related/ancillary market outlook
• Fig. 17 Penetration and growth prospect mapping
• Fig. 18 Industry value chain analysis
• Fig. 19 Next Generation Tissue Biomarkers market driver impact
• Fig. 20 Next Generation Tissue Biomarkers market restraint impact
• Fig. 21 Next Generation Tissue Biomarkers market strategic initiatives analysis
• Fig. 22 Next Generation Tissue Biomarkers market: Product movement analysis
• Fig. 23 Next Generation Tissue Biomarkers market: Product outlook and key takeaways
• Fig. 24 Reagents & Assays market estimates and forecast, 2018 - 2030
• Fig. 25 Instruments & Platforms market estimates and forecast, 2018 - 2030
• Fig. 26 Software & AI market estimates and forecast, 2018 - 2030
• Fig. 27 Next Generation Tissue Biomarkers Market: Type movement analysis
• Fig. 28 Next Generation Tissue Biomarkers market: Type outlook and key takeaways
• Fig. 29 Genomic Biomarkers market estimates and forecasts, 2018 - 2030
• Fig. 30 Proteomic Biomarkers market estimates and forecasts,2018 - 2030
• Fig. 31 Epigenetic Biomarkers market estimates and forecasts, 2018 - 2030
• Fig. 32 Transcriptomic Biomarkers market estimates and forecasts,2018 - 2030
• Fig. 33 Metabolomic Biomarkers market estimates and forecasts, 2018 - 2030
• Fig. 34 Next Generation Tissue Biomarkers Market: Technology movement analysis
• Fig. 35 Next Generation Tissue Biomarkers market: Technology outlook and key takeaways
• Fig. 36 Immunohistochemistry market estimates and forecasts, 2018 - 2030
• Fig. 37 Next-Generation Sequencing (NGS) market estimates and forecasts,2018 - 2030
• Fig. 38 Mass Spectrometry (MS)-based Proteomics market estimates and forecasts,2018 - 2030
• Fig. 39 Spatial Biology Platforms market estimates and forecasts,2018 - 2030
• Fig. 40 Digital Pathology & AI Analysis market estimates and forecasts,2018 - 2030
• Fig. 41 Others market estimates and forecasts,2018 - 2030
• Fig. 42 Next Generation Tissue Biomarkers Market: Application movement analysis
• Fig. 43 Next Generation Tissue Biomarkers market: Application outlook and key takeaways
• Fig. 44 Oncology market estimates and forecasts, 2018 - 2030
• Fig. 45 Companion Diagnostics market estimates and forecasts,2018 - 2030
• Fig. 46 Drug Discovery & Development market estimates and forecasts,2018 - 2030
• Fig. 47 Neurology market estimates and forecasts,2018 - 2030
• Fig. 48 Others market estimates and forecasts,2018 - 2030
• Fig. 49 Next Generation Tissue Biomarkers market: End Use movement analysis
• Fig. 50 Next Generation Tissue Biomarkers market: End Use outlook and key takeaways
• Fig. 51 Hospitals & Reference Labs market estimates and forecasts, 2018 - 2030
• Fig. 52 Pharma & Biotech Companies market estimates and forecasts,2018 - 2030
• Fig. 53 Academic and Research Institutes market estimates and forecasts, 2018 - 2030
• Fig. 54 Contract Research Organizations (CROs) market estimates and forecasts, 2018 - 2030
• Fig. 55 Global Next Generation Tissue Biomarkers market: Regional movement analysis
• Fig. 56 Global Next Generation Tissue Biomarkers market: Regional outlook and key takeaways
• Fig. 57 Global Next Generation Tissue Biomarkers market share and leading players
• Fig. 58 North America market share and leading players
• Fig. 59 Europe market share and leading players
• Fig. 60 Asia Pacific market share and leading players
• Fig. 61 Latin America market share and leading players
• Fig. 62 Middle East & Africa market share and leading players
• Fig. 63 North America
• Fig. 64 Europe
• Fig. 65 Asia Pacific
• Fig. 66 Latin America
• Fig. 67 MEA
• Fig. 68 North America, by country
• Fig. 69 North America
• Fig. 70 North America market estimates and forecasts, 2018 - 2030
• Fig. 71 U.S.
• Fig. 72 U.S. market estimates and forecasts, 2018 - 2030
• Fig. 73 Canada
• Fig. 74 Canada market estimates and forecasts, 2018 - 2030
• Fig. 75 Mexico
• Fig. 76 Mexico market estimates and forecasts, 2018 - 2030
• Fig. 77 Europe
• Fig. 78 Europe market estimates and forecasts, 2018 - 2030
• Fig. 79 UK
• Fig. 80 UK market estimates and forecasts, 2018 - 2030
• Fig. 81 Germany
• Fig. 82 Germany market estimates and forecasts, 2018 - 2030
• Fig. 83 France
• Fig. 84 France market estimates and forecasts, 2018 - 2030
• Fig. 85 Italy
• Fig. 86 Italy market estimates and forecasts, 2018 - 2030
• Fig. 87 Spain
• Fig. 88 Spain market estimates and forecasts, 2018 - 2030
• Fig. 89 Denmark
• Fig. 90 Denmark market estimates and forecasts, 2018 - 2030
• Fig. 91 Sweden
• Fig. 92 Sweden market estimates and forecasts, 2018 - 2030
• Fig. 93 Norway
• Fig. 94 Norway market estimates and forecasts, 2018 - 2030
• Fig. 95 Asia Pacific
• Fig. 96 Asia Pacific market estimates and forecasts, 2018 - 2030
• Fig. 97 China
• Fig. 98 China market estimates and forecasts, 2018 - 2030
• Fig. 99 Japan
• Fig. 100 Japan market estimates and forecasts, 2018 - 2030
• Fig. 101 India
• Fig. 102 India market estimates and forecasts, 2018 - 2030
• Fig. 103 Thailand
• Fig. 104 Thailand market estimates and forecasts, 2018 - 2030
• Fig. 105 South Korea
• Fig. 106 South Korea market estimates and forecasts, 2018 - 2030
• Fig. 107 Australia
• Fig. 108 Australia market estimates and forecasts, 2018 - 2030
• Fig. 109 Latin America
• Fig. 110 Latin America market estimates and forecasts, 2018 - 2030
• Fig. 111 Brazil
• Fig. 112 Brazil market estimates and forecasts, 2018 - 2030
• Fig. 113 Argentina
• Fig. 114 Argentina market estimates and forecasts, 2018 - 2030
• Fig. 115 Middle East and Africa
• Fig. 116 Middle East and Africa market estimates and forecasts, 2018 - 2030
• Fig. 117 South Africa
• Fig. 118 South Africa market estimates and forecasts, 2018 - 2030
• Fig. 119 Saudi Arabia
• Fig. 120 Saudi Arabia market estimates and forecasts, 2018 - 2030
• Fig. 121 UAE
• Fig. 122 UAE market estimates and forecasts, 2018 - 2030
• Fig. 123 Kuwait
• Fig. 124 Kuwait market estimates and forecasts, 2018 - 2030
• Fig. 125 Market share of key market players - Next Generation Tissue Biomarkers market

Next Generation Tissue Biomarkers Market Growth & Trends:

The global next generation tissue biomarkers market size is anticipated to reach USD 5.98 billion by 2030 and is projected to grow at a CAGR of 12.74% during the forecast period, according to a new report by Grand View Research, Inc. Key driving factors such as increasing prevalence of chronic diseases, technological advancements in biomarker detection techniques, and rising demand for personalized medicines are responsible for market growth. There is a global increase in the incidence of chronic diseases such as diabetes, cancer, and other autoimmune diseases.

Increasing technological advancements for detecting next generation tissue biomarkers boost the growth of the market. The development of high throughput screening technologies such as next-generation sequencing (NGS) has significantly enhanced the ability to analyze genetic mutations and gene expression profiles in cancer tissues. Furthermore, liquid biopsies, high throughput screening technologies, epigenetic profiling, and microRNA-based biosensors are in practice for next generation tissue biomarker detection. Collectively, these technological advancements are transforming the landscape of tissue biomarker discovery, leading to more accurate diagnostics, personalized treatment strategies, and improved patient outcomes. AI and machine learning algorithms are being incorporated into digital pathology, automating the analysis of tissue images. The growing demand for personalized medicines is another key factor responsible for market growth. These personalized medicines are increasingly leveraging next-generation tissue biomarkers to tailor treatments to individual patients.

For the detection of biomarkers, in February 2025, Alida Biosciences (AlidaBio), a company in epigenomic research tools, officially announced the full commercial launch of its EpiPlex platform. This groundbreaking platform is the first to simultaneously detect and quantify multiple RNA modifications through short-read sequencing while also providing gene expression data.

In February 2025, Biofidelity, a provider of genomic solutions, unveiled details about the launch of Enspyre, an innovative target enrichment technology with a wide range of potential applications. A groundbreaking target enrichment technology that greatly improves next-generation sequencing (NGS) efficiency by selectively eliminating background DNA.

In September 2024, Genialis, an RNA biomarker company, announced the launch of Genialis krasID, the first biomarker algorithm capable of predicting patient response and clinical benefit to KRAS inhibitors (KRASi) across different tissue histologies and mutation types. Genialis krasID can assist in guiding drug development from early preclinical stages, such as compound/MOA differentiation and selection, to clinical trials.

Another novel senescent cell targeting molecules was developed in October 2024. Illumina, Inc., a company in DNA sequencing and array-based technologies, introduced its MiSeq i100 Series of sequencing systems today, offering unmatched benchtop speed and ease of use to enhance next-generation sequencing (NGS) in laboratories.

In September 2021, Roche announced the release of the AVENIO Tumor Tissue CGP Kit. This new kit enhances the existing CGP portfolio from Roche and Foundation Medicine, enabling laboratories to conduct more extensive oncology research in-house. The introduction of this kit will greatly increase global access to genomic profiling by offering an in-house solution for those unable to access our tests through centralized laboratories, the company stated.

Next Generation Tissue Biomarkers Market Report Highlights:

• Based on product, reagents and assays accounted for the largest revenue share of 55.97% in 2024. This segment is expected to see rapid expansion due to its broad applicability in biopharmaceutical research. A key driving factor is the growing need for early disease detection and diagnostics, which has resulted in high demand for accurate, reliable, and rapid diagnostics, contributing to market growth.
• Based on type, the genomic biomarker segment dominated the market in 2024 owing to the rising demand for innovative therapies, growing competition for early disease detection, and significant R&D investments. Metabolomic biomarkers are expected to grow fastest over the forecast period. Metabolomic biomarkers refer to specific metabolic changes or substances in the body that can be measured and used to identify disease states, predict disease risk, and monitor responses to treatments.
• Based on technology, the next generation sequencing segment dominated the market with the largest revenue share in 2024. Next Generation Sequencing (NGS) refers to the huge DNA sequencing methods that aid in genomic discovery. The spatial genomics biology segment is anticipated to witness growth at the fastest CAGR from 2024 to 2030. The advancements in genome editing tools, such as the CRISPR/Cas9 system, have facilitated spatial genomics biology adoption, driving market growth.
• Based on application, the oncology segment dominated the market with the largest revenue share in 2024. The growing demand for precision medicine drives the segment growth and targeted cancer therapies. Companion diagnostics are expected to grow fastest over the forecast period. The companion diagnostics market is experiencing significant product expansion, with new assays being developed for various cancer types, autoimmune diseases, and neurological disorders.
• Based on end use, the hospitals & reference labs segment dominated the market with the largest revenue share in 2024. Hospitals and reference labs are rapidly adopting next generation tissue biomarkers to enhance efficiency, accuracy, and accessibility. Contract research organizations are projected to grow significantly during the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Technology
  • 1.2.3. Application
  • 1.2.4. Type
  • 1.2.5. End Use
  • 1.2.6. Regional scope
  • 1.2.7. Estimates and forecasts timeline.
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product outlook
  • 2.2.2. Technology outlook
  • 2.2.3. Application outlook
  • 2.2.4. Type outlook
  • 2.2.5. End Use outlook
  • 2.2.6. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Next Generation Tissue Biomarkers Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rise of Precision Medicine and Companion Diagnostics
    • 3.2.1.2. Technological Advancements in Spatial Biology and NGS
    • 3.2.1.3. Expansion of Clinical Utility Across Disease Areas
    • 3.2.1.4. Growth in Digital Pathology and AI-Driven Analysis
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High Cost of Multi-Omic Platforms and Reagents
    • 3.2.2.2. Data Privacy and Infrastructure Barriers in AI Adoption
• 3.3. Next Generation Tissue Biomarkers Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis

Chapter 4. Next Generation Tissue Biomarkers Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Next Generation Tissue Biomarkers Market: Product Movement Analysis
• 4.3. Next Generation Tissue Biomarkers Market Size & Trend Analysis, by product, 2018 to 2030 (USD Million)
• 4.4. Reagents & Assays
  • 4.4.1. Reagents & Assays Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.5. Instruments & Platforms
  • 4.5.1. Instruments & Platforms Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.6. Software & AI
  • 4.6.1. Software & AI Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Next Generation Tissue Biomarkers Market: Type Estimates & Trend Analysis

• 5.1. Type Market Share, 2024 & 2030
• 5.2. Segment Dashboard
• 5.3. Next Generation Tissue Biomarkers Market by Type Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 5.5. Genomic Biomarkers
  • 5.5.1. Genomic Biomarkers Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Proteomic Biomarkers
  • 5.6.1. Proteomic Biomarkers Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.7. Proteomic Biomarkers
  • 5.7.1. Proteomic Biomarkers Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.8. Epigenetic Biomarkers
  • 5.8.1. Epigenetic Biomarkers Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.9. Transcriptomic Biomarkers
  • 5.9.1. Transcriptomic Biomarkers Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.10. Metabolomic Biomarkers
  • 5.10.1. Metabolomic Biomarkers Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Next Generation Tissue Biomarkers Market: Technology Estimates & Trend Analysis

• 6.1. Technology Market Share, 2024 & 2030
• 6.2. Segment Dashboard
• 6.3. Next Generation Tissue Biomarkers Market by Technology Outlook
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 6.5. Immunohistochemistry
  • 6.5.1. Immunohistochemistry Market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Next-Generation Sequencing (NGS)
  • 6.6.1. Next-Generation Sequencing (NGS) Market estimates and forecasts 2018 to 2030 (USD Million)
• 6.7. Mass Spectrometry (MS)-based Proteomics
  • 6.7.1. Mass Spectrometry (MS)-based Proteomics Market estimates and forecasts 2018 to 2030 (USD Million)
• 6.8. Spatial Biology Platforms
  • 6.8.1. Spatial Biology Platforms Market estimates and forecasts 2018 to 2030 (USD Million)
• 6.9. Digital Pathology & AI Analysis
  • 6.9.1. Digital Pathology & AI Analysis Market estimates and forecasts 2018 to 2030 (USD Million)
• 6.10. Others
  • 6.10.1. Others Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Next Generation Tissue Biomarkers Market: Application Estimates & Trend Analysis

• 7.1. Application Market Share, 2024 & 2030
• 7.2. Segment Dashboard
• 7.3. Next Generation Tissue Biomarkers Market by Application Outlook
• 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 7.5. Oncology
  • 7.5.1. Oncology Market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Companion Diagnostics
  • 7.6.1. Companion Diagnostics Market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. Drug Discovery & Development
  • 7.7.1. Drug Discovery & Development Market estimates and forecasts 2018 to 2030 (USD Million)
• 7.8. Neurology
  • 7.8.1. Neurology Market estimates and forecasts 2018 to 2030 (USD Million)
• 7.9. Others
  • 7.9.1. Others Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Next Generation Tissue Biomarkers Market: End Use Estimates & Trend Analysis

• 8.1. End Use Market Share, 2024 & 2030
• 8.2. Segment Dashboard
• 8.3. Next Generation Tissue Biomarkers Market by End Use Outlook
• 8.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 8.5. Hospitals & Reference Labs
  • 8.5.1. Hospitals & Reference Labs Market estimates and forecasts 2018 to 2030 (USD Million)
• 8.6. Pharma & Biotech Companies
  • 8.6.1. Pharma & Biotech Companies Market estimates and forecasts 2018 to 2030 (USD Million)
• 8.7. Academic and Research Institutes
  • 8.7.1. Academic and Research Institutes Market estimates and forecasts 2018 to 2030 (USD Million)
• 8.8. Contract Research Organizations (CROs)
  • 8.8.1. Contract Research Organizations (CROs) Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Next Generation Tissue Biomarkers Market: Regional Estimates & Trend Analysis

• 9.1. Regional Market Share Analysis, 2024 & 2030
• 9.2. Regional Market Dashboard
• 9.3. Global Regional Market Snapshot
• 9.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 9.5. North America
  • 9.5.1. North America
  • 9.5.2. U.S.
    • 9.5.2.1. Key country dynamics
    • 9.5.2.2. Regulatory framework/Reimbursement
    • 9.5.2.3. Competitive scenario
    • 9.5.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.5.3. Canada
    • 9.5.3.1. Key country dynamics
    • 9.5.3.2. Regulatory framework/Reimbursement
    • 9.5.3.3. Competitive scenario
    • 9.5.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.5.4. Mexico
    • 9.5.4.1. Key country dynamics
    • 9.5.4.2. Regulatory framework/Reimbursement
    • 9.5.4.3. Competitive scenario
    • 9.5.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 9.6. Europe
  • 9.6.1. Europe
  • 9.6.2. UK
    • 9.6.2.1. Key country dynamics
    • 9.6.2.2. Regulatory framework/Reimbursement
    • 9.6.2.3. Competitive scenario
    • 9.6.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.3. Germany
    • 9.6.3.1. Key country dynamics
    • 9.6.3.2. Regulatory framework/Reimbursement
    • 9.6.3.3. Competitive scenario
    • 9.6.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.4. France
    • 9.6.4.1. Key country dynamics
    • 9.6.4.2. Regulatory framework/Reimbursement
    • 9.6.4.3. Competitive scenario
    • 9.6.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.5. Italy
    • 9.6.5.1. Key country dynamics
    • 9.6.5.2. Regulatory framework/Reimbursement
    • 9.6.5.3. Competitive scenario
    • 9.6.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.6. Spain
    • 9.6.6.1. Key country dynamics
    • 9.6.6.2. Regulatory framework/Reimbursement
    • 9.6.6.3. Competitive scenario
    • 9.6.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.7. Norway
    • 9.6.7.1. Key country dynamics
    • 9.6.7.2. Regulatory framework/Reimbursement
    • 9.6.7.3. Competitive scenario
    • 9.6.7.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.8. Sweden
    • 9.6.8.1. Key country dynamics
    • 9.6.8.2. Regulatory framework/Reimbursement
    • 9.6.8.3. Competitive scenario
    • 9.6.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.9. Denmark
    • 9.6.9.1. Key country dynamics
    • 9.6.9.2. Regulatory framework/Reimbursement
    • 9.6.9.3. Competitive scenario
    • 9.6.9.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 9.7. Asia Pacific
  • 9.7.1. Asia Pacific
  • 9.7.2. Japan
    • 9.7.2.1. Key country dynamics
    • 9.7.2.2. Regulatory framework/Reimbursement
    • 9.7.2.3. Competitive scenario
    • 9.7.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.7.3. China
    • 9.7.3.1. Key country dynamics
    • 9.7.3.2. Regulatory framework/Reimbursement
    • 9.7.3.3. Competitive scenario
    • 9.7.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.7.4. India
    • 9.7.4.1. Key country dynamics
    • 9.7.4.2. Regulatory framework/Reimbursement
    • 9.7.4.3. Competitive scenario
    • 9.7.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.7.5. Australia
    • 9.7.5.1. Key country dynamics
    • 9.7.5.2. Regulatory framework/Reimbursement
    • 9.7.5.3. Competitive scenario
    • 9.7.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.7.6. South Korea
    • 9.7.6.1. Key country dynamics
    • 9.7.6.2. Regulatory framework/Reimbursement
    • 9.7.6.3. Competitive scenario
    • 9.7.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.7.7. Thailand
    • 9.7.7.1. Key country dynamics
    • 9.7.7.2. Regulatory framework/Reimbursement
    • 9.7.7.3. Competitive scenario
    • 9.7.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 9.8. Latin America
  • 9.8.1. Latin America
  • 9.8.2. Brazil
    • 9.8.2.1. Key country dynamics
    • 9.8.2.2. Regulatory framework/Reimbursement
    • 9.8.2.3. Competitive scenario
    • 9.8.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.8.3. Argentina
    • 9.8.3.1. Key country dynamics
    • 9.8.3.2. Regulatory framework/Reimbursement
    • 9.8.3.3. Competitive scenario
    • 9.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 9.9. MEA
  • 9.9.1. MEA
  • 9.9.2. South Africa
    • 9.9.2.1. Key country dynamics
    • 9.9.2.2. Regulatory framework/Reimbursement
    • 9.9.2.3. Competitive scenario
    • 9.9.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.9.3. Saudi Arabia
    • 9.9.3.1. Key country dynamics
    • 9.9.3.2. Regulatory framework/Reimbursement
    • 9.9.3.3. Competitive scenario
    • 9.9.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.9.4. UAE
    • 9.9.4.1. Key country dynamics
    • 9.9.4.2. Regulatory framework/Reimbursement
    • 9.9.4.3. Competitive scenario
    • 9.9.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.9.5. Kuwait
    • 9.9.5.1. Key country dynamics
    • 9.9.5.2. Regulatory framework
    • 9.9.5.3. Competitive scenario
    • 9.9.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 10. Competitive Landscape

• 10.1. Recent Developments & Impact Analysis, By Key Market Participants
• 10.2. Company/Competition Categorization
• 10.3. Vendor Landscape
  • 10.3.1. List of key distributors and channel partners
  • 10.3.2. Key customers
  • 10.3.3. Key company market share analysis, 2024
  • 10.3.4. Roche Diagnostics / Ventana Medical Systems
    • 10.3.4.1. Company overview
    • 10.3.4.2. Financial performance
    • 10.3.4.3. Services benchmarking
    • 10.3.4.4. Strategic initiatives
  • 10.3.5. Agilent Technologies / Dako
    • 10.3.5.1. Company overview
    • 10.3.5.2. Financial performance
    • 10.3.5.3. Services benchmarking
    • 10.3.5.4. Strategic initiatives
  • 10.3.6. Thermo Fisher Scientific
    • 10.3.6.1. Company overview
    • 10.3.6.2. Financial performance
    • 10.3.6.3. Services benchmarking
    • 10.3.6.4. Strategic initiatives
  • 10.3.7. Leica Biosystems (Danaher Corporation)
    • 10.3.7.1. Company overview
    • 10.3.7.2. Financial performance
    • 10.3.7.3. Services benchmarking
    • 10.3.7.4. Strategic initiatives
  • 10.3.8. Illumina
    • 10.3.8.1. Company overview
    • 10.3.8.2. Financial performance
    • 10.3.8.3. Services benchmarking
    • 10.3.8.4. Strategic initiatives
  • 10.3.9. Qiagen
    • 10.3.9.1. Company overview
    • 10.3.9.2. Financial performance
    • 10.3.9.3. Services benchmarking
    • 10.3.9.4. Strategic initiatives
  • 10.3.10. NeoGenomics
    • 10.3.10.1. Company overview
    • 10.3.10.2. Financial performance
    • 10.3.10.3. Services benchmarking
    • 10.3.10.4. Strategic initiatives
  • 10.3.11. NanoString Technologies
    • 10.3.11.1. Company overview
    • 10.3.11.2. Financial performance
    • 10.3.11.3. Services benchmarking
    • 10.3.11.4. Strategic initiatives
  • 10.3.12. Akoya Biosciences
    • 10.3.12.1. Company overview
    • 10.3.12.2. Financial performance
    • 10.3.12.3. Services benchmarking
    • 10.3.12.4. Strategic initiatives
  • 10.3.13. Bio-Techne / ACD
    • 10.3.13.1. Company overview
    • 10.3.13.2. Financial performance
    • 10.3.13.3. Services benchmarking
    • 10.3.13.4. Strategic initiatives
  • 10.3.14. Guardant Health
    • 10.3.14.1. Company overview
    • 10.3.14.2. Financial performance
    • 10.3.14.3. Services benchmarking
    • 10.3.14.4. Strategic initiatives